الفهرس 
Classification of periodontal diseases:
Surgical periodontal therapyOnly 14 pages are availabe for public view
 |  | from | 183 |  |  |
| | | from | 183 | | |
Abstract
Background: Injectable platelet rich fibrin (i-PRF) is a bioactive substance that can be obtained via low- speed centrifugation of a blood sample and is capable of promoting tissue regeneration. Piroxicam is a non-steroidal antiinflammatory of the oxicam group that can be used as an adjunctive to nonsurgical periodontal therapy. In view of the importance and prevalence of chronic periodontitis, there is still an urgent need to search for an effective therapy that is less expensive, easy to use, and readily available with no side effects. Aim of work: to evaluate the efficacy of piroxicam gel versus injectable platelet rich fibrin in treatment of stage III periodontitis. Materials and method: Forty sites (the deepest periodontal pockets) were selected from six female patients diagnosed as having stage III periodontitis were randomly assigned to 2 groups: group I (GӀ) and group II (GII). Twenty sites in (GI): Was treated by piroxicam gel, and twenty sites in (GӀӀ) were treated by Injectable platelet rich fibrin. All patients had received scaling and root planing (SRP).The application was done two weeks after SRP and applied for five times one application every two weeks over 10 weeks. The comparison was assessed clinically and immunologically. Clinically, via recorded: probing pocket depth (PPD), clinical attachment loss (CAL), and bleeding on probing (BOP). Immunologically, via measuring: the levels of MMPs-8 in gingival cervical fluid (GCF) samples. Clinical and immunological were recorded at baseline (before SRP), four weeks (two weeks after first application), eight weeks (at fourth application), and twelve weeks (two weeks after the last application). Results: Both groups showed significant improvement in all clinical and immunological parameters. Comparing GI and GII at each follow-up time point, there was significant amelioration in all assessed parameters in favor to GII. Conclusion: The use of i-PRF is preferred over the use of piroxicam gel in the treatment of stage III chronic periodontitis, as it gives better clinical and immunological results.